Genelux GNLX 深 滬
等待開盤 09-25 09:30:00 美东时间
2.44
-0.075
-2.98%
華盛通- 最 高2.5244
- 今 開2.51
- 成交量 11.21万股
- 最 低 2.4301
- 昨 收 2.515
- 總市值 1.10亿
- 52周最高 8.535
- 市盈率 靜 --
- 換手率 0.25%
- 52周最低 2.29
- 委 比 -20.34%
- 總股本 4524.53万
- 歷史最高 40.98
- 量 比 0.72
- 振 幅 3.75%
- 歷史最低 1.60
- 每 手 1
- 風險率 1.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
A platinum-relapsed small cell lung cancer (SCLC) patient achieved a 16.7-month progression-free survival (PFS) and an 84.6% reduction in target lesion size after receiving Olvi-Vec followed by platinum rechallenge, surpassing outcomes from first-line therapy. These findings highlight Olvi-Vec's potential to enhance anti-tumor activity and platinum-based chemotherapy response. Genelux Corporation's Phase 1b/2 OLVI-VEC-202-SCLC trial continues to ...
09-09 20:01
Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate
Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 5 percent decrease over losses of $(0.20) per share from the same period last year.
08-14 04:33
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $20
Benchmark analyst Bruce D. Jackson maintains Genelux (NASDAQ:GNLX) with a Speculative Buy and lowers the price target from $23 to $20.
03-20 23:45
Genelux Q4 EPS $(0.24) Misses $(0.21) Estimate
Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.21) by 12.68 percent. This is a 4 percent increase over losses of $(0.25) per share from the same
03-20 04:30
Genelux Prices ~$20M Public Offering Of 6.67M Shares At A Price Of $3/Share
Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the
01-08 22:14
Genelux Announces Interim Results From Two Ongoing Trials, Phase 1b/2 SCLC And Phase 2 VIRO-25, Evaluating Systemic Administration Of Olvi-Vec In Patients With Progressive SCLC And NSCLC
-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing –-- In
01-05 21:08
Genelux Appoints Veteran Oncologist Jason Litten as CMO
Genelux Corp. ( ($GNLX) ) has issued an update. On December 30, 2025, Genelux C...
01-03 05:30
Genelux Q3 EPS $(0.21), Inline
Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 10.53 percent decrease over losses of $(0.19) per share from the same period last year.
2025-11-06 06:05
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
2025-10-22 10:10
